Early Experiences with Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Failed Target Therapy
이종훈, 강민용, 정재훈, 성현환, 전하림, 정병창, 전성수, 이현무, 박세훈, 김빈나리, 권기영, 서성일,
소속 상세정보
이종훈 ( Lee Jong-Hoon )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Urology
강민용 ( Kang Min-Yong )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Urology
정재훈 ( Chung Jae-Hoon )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Urology
성현환 ( Sung Hyun-Hwan )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Urology
전하림 ( Jeon Ha-Lim )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Urology
정병창 ( Jeong Byung-Chang )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Urology
전성수 ( Jeon Seong-Soo )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Urology
이현무 ( Lee Hyun-Moo )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Urology
박세훈 ( Park Se-Hoon )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Hematology-Oncology
김빈나리 ( Kim Binnari )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Pathology & Translational Genomics
권기영 ( Kwon Ghee-Young )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Pathology & Translational Genomics
서성일 ( Seo Seong-Il )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Urology
Abstract
Purpose: The efficacy of nivolumab in metastatic renal cell carcinoma (mRCC) has been proven. However, the nivolumab experience in Korean patients with mRCC is still poorly reported. We report initial experiences with the efficacy and safety of nivolumab in patients with mRCC.
Materials and Methods: We retrospectively reviewed records for 25 patients with mRCC who had failed targeted therapy and were treated by nivolumab (2 mg/kg, every 2 weeks) at a single institution. The primary endpoint was objective response rate (ORR), and secondary endpoints were progression-free survival (PFS), safety profiles, and ORR in a programmed cell death receptor ligand 1 (PD-L1) expression subgroup.
Results: The median age was 60 years and 16 patients (64%) were male. Objective responses were achieved in 8 patients (32.0%) (complete response, 1; partial response, 7). Median PFS was 3.0 months (95% confidence interval, 1.46?4.53). Treatment-related adverse events (AEs) of any grade were observed in 19 patients (76.0%) with 6 (24.0%) experiencing grade 3 to 4 treatment-related AEs. In subgroups by PD-L1 expression levels classified as 1% or greater and less than 1%, ORR was 50% and 0%, respectively.
Conclusions: This study showed the efficacy and safety of initial experiences with nivolumab in Korean patients with mRCC who had failed targeted therapy. Our results were comparable to recent clinical trials on nivolumab in mRCC.
키워드
Metastasis; Monoclonal antibody; Programmed cell death 1 ligand 1; Renal cell carcinoma; Treatment outcome
원문 및 링크아웃 정보
등재저널 정보